Drug Type Small molecule drug |
Synonyms Beloranib, CKD-732, TNP-470 analogue + [2] |
Target |
Mechanism METAP2 inhibitors(Methionine aminopeptidase 2 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 1 |
First Approval Date- |
RegulationOrphan Drug (US) |
Molecular FormulaC60H84N2O16 |
InChIKeyZKEMUPZLDSXZCX-CEVDDVLHSA-N |
CAS Registry529511-79-3 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Beloranib Hemioxalate | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Prader-Willi Syndrome | Phase 3 | US | 01 Sep 2014 | |
Diabetes Mellitus, Type 2 | Phase 2 | AU | 01 Dec 2014 | |
Craniopharyngioma | Phase 2 | US | 01 Apr 2014 | |
Craniopharyngioma | Phase 2 | AU | 01 Apr 2014 | |
Hypothalamic Diseases | Phase 2 | US | 01 Apr 2014 | |
Hypothalamic Diseases | Phase 2 | AU | 01 Apr 2014 | |
Wounds and Injuries | Phase 2 | US | 01 Apr 2014 | |
Wounds and Injuries | Phase 2 | AU | 01 Apr 2014 | |
Obesity | Phase 2 | AU | 01 Aug 2012 | |
Metastatic Colorectal Carcinoma | Phase 1 | KR | 20 May 2010 |
Phase 2 | 12 | beloranib | cbotclpnue(iqsndczjmt): difference = -3.2 (95% CI, -5.4 to -0.9) | Positive | 01 Aug 2017 | ||
Placebo |